Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

591 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions.
Brun S, Bestion E, Raymond E, Bassissi F, Jilkova ZM, Mezouar S, Rachid M, Novello M, Tracz J, Hamaï A, Lalmanach G, Vanderlynden L, Legouffe R, Stauber J, Schubert T, Plach MG, Courcambeck J, Drouot C, Jacquemot G, Serdjebi C, Roth G, Baudoin JP, Ansaldi C, Decaens T, Halfon P. Brun S, et al. Among authors: raymond e. Autophagy. 2022 Mar;18(3):678-694. doi: 10.1080/15548627.2021.1988357. Epub 2021 Nov 5. Autophagy. 2022. PMID: 34740311 Free PMC article.
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
Harding JJ, Awada A, Roth G, Decaens T, Merle P, Kotecki N, Dreyer C, Ansaldi C, Rachid M, Mezouar S, Menut A, Bestion EN, Paradis V, Halfon P, Abou-Alfa GK, Raymond E. Harding JJ, et al. Among authors: raymond e. Liver Cancer. 2022 Feb 15;11(3):268-277. doi: 10.1159/000522418. eCollection 2022 Jun. Liver Cancer. 2022. PMID: 35949290 Free PMC article.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Decaens T, et al. Among authors: raymond e. Br J Cancer. 2021 Jul;125(2):190-199. doi: 10.1038/s41416-021-01334-9. Epub 2021 Apr 6. Br J Cancer. 2021. PMID: 33824476 Free PMC article. Clinical Trial.
Novel molecular therapies in hepatocellular carcinoma.
Faivre S, Bouattour M, Raymond E. Faivre S, et al. Among authors: raymond e. Liver Int. 2011 Jan;31 Suppl 1:151-60. doi: 10.1111/j.1478-3231.2010.02395.x. Liver Int. 2011. PMID: 21205154 Review.
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Decaens T, et al. Among authors: raymond e. Br J Cancer. 2021 Aug;125(3):465. doi: 10.1038/s41416-021-01403-z. Br J Cancer. 2021. PMID: 34079081 Free PMC article. No abstract available.
mTOR-targeted therapy of cancer with rapamycin derivatives.
Vignot S, Faivre S, Aguirre D, Raymond E. Vignot S, et al. Among authors: raymond e. Ann Oncol. 2005 Apr;16(4):525-37. doi: 10.1093/annonc/mdi113. Epub 2005 Feb 22. Ann Oncol. 2005. PMID: 15728109 Free article. Review.
591 results